ADDITIONAL THERAPEUTIC USE
The invention relates to the use of an AT 1 receptor antagonist or or an AT 2 receptor modulator, respectively, or a pharmaceutically acceptable salt thereof, for producing a pharmaceutical preparation for the treatment of conditions or diseases associated with the increase of AT 1 receptors in the sub-epithelial area or increase of AT 2 receptors in the epithelia.
1 . A compressed tablet comprising valsartan, microcrystalline cellulose and crospovidone, wherein the weight ratio of valsartan to microcrystalline cellulose is from 1.4:1 to 1:1.
2 . A tablet according to claim 1 comprising less than 13% by weight of crospovidone.
3 . A tablet according to claim 1 , wherein the weight ratio of microcrystalline cellulose to crospovidone is from 7:1 to 3.6:1.
4 . A tablet according to claim 1 , wherein the tablet comprises more than 250 mg and up to 360 mg valsartan as an active agent.
5 . A tablet according to claim 1 , wherein the tablet comprises 320 mg valsartan as an active agent.
6 . A tablet according to claim 1 , comprising
40 mg of valsartan
27 mg of microcrystalline cellulose and
7.5 mg of crospovidone.
7 . A tablet according to claim 1 , comprising
80 mg of valsartan
54 mg of microcrystalline cellulose and
15 mg of crospovidone.
8 . A tablet according to claim 1 comprising
160 mg of valsartan
108 mg of microcrystalline cellulose and
30 mg of crospovidone.
9 . A tablet according to claim 1 , comprising
320 mg of valsartan
216 mg of microcrystalline cellulose and
60 mg of crospovidone.
10 . A compressed tablet comprising valsartan, more than 30% up to 65% by weight of microcrystalline cellulose, and less than 13% by weight of crospovidone.
11 . The tablet of claim 10 further comprising 20% to 65% by weight of valsartan.
12 . The tablet of claim 10 comprising:
20 to 65% by weight of valsartan
31% to 65% by weight of microcrystalline cellulose
2% to 10% by weight of crospovidone
1 to 10% by weight of magnesium stearate and
0.5% to 5% by weight of colloidal anhydrous silica.